CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is an oncology-focused biopharmaceutical company that became publicly traded through a business combination with TenX Keane Acquisition Corp., a blank-check company sponsored by TenX Keane Sponsor LLC that completed its IPO in 2021 targeting the healthcare and life sciences sector. The company, spun out of Citius Pharmaceuticals to focus on cancer therapeutics, retained the TENK ticker following the close of the de-SPAC transaction. On August 5, 2026, the company filed a 424B3 prospectus supplement with the SEC, accession number 0001213900-26-085679, in connection with the resale of registered shares. Sign up at SpacDesk for full filing history, sponsor data, and analytics on TENK and the broader SPAC market.